MAIA Biotechnology presented Phase 3 THIO-104 trial design at ASCO 2026 assessing telomere-targeting agent ateganosine plus PD-(L)1 inhibitors in third-line NSCLC resistant to checkpoint inhibitors and chemotherapy. First patient was dosed December 2025 and enrollment is underway in Europe and Asia with overall survival versus chemotherapy as primary endpoint.
MAIA showcased the THIO-104 trial design at the 2026 ASCO Annual Meeting, detailing a randomized, open-label study comparing ateganosine sequenced with PD-(L)1 inhibitors against standard chemotherapy. The poster outlined inclusion criteria focused on third-line NSCLC patients who developed resistance to checkpoint inhibitors and prior chemotherapy.
The first patient received ateganosine in December 2025, and sites across Europe and Asia are actively screening and enrolling participants. The trial’s co-primary objectives are to compare median overall survival against investigator-choice chemotherapy and to evaluate the safety and tolerability of sequential ateganosine and checkpoint inhibitor treatment.
